

# Yu Yao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6399011/publications.pdf>

Version: 2024-02-01

58  
papers

3,257  
citations

236925

25  
h-index

182427

51  
g-index

59  
all docs

59  
docs citations

59  
times ranked

5262  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
2	CTNI-52. RETROSPECTIVE ANALYSIS OF USING RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR CHINESE PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	1.2	0
3	NCOG-14. REAL-WORLD RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS IN THE TREATMENT OF HIGH-GRADE GLIOMA BASED ON CHINESE POPULATION. <i>Neuro-Oncology</i> , 2021, 23, vi154-vi155.	1.2	0
4	Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. , 2020, 8, e000154.		23
5	Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1436-1446.	1.2	51
6	ATIM-11. TUMOR-INFILTRATING LYMPHOCYTES EXPRESSING ANTI-PD-1 ANTIBODY EXHIBIT A PROMISING EFFICACY AND SURVIVAL BENEFIT IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME. <i>Neuro-Oncology</i> , 2019, 21, vi3-vi4.	1.2	0
7	TMIC-11. ENHANCED B7-H4 EXPRESSION IN GLIOMAS WITH LOW PD-L1 EXPRESSION IDENTIFIES COLD TUMORS. <i>Neuro-Oncology</i> , 2019, 21, vi249-vi249.	1.2	0
8	Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma. <i>Disease Markers</i> , 2019, 2019, 1-14.	1.3	22
9	Cerebral ischemia induces angiogenesis in the peri-infarct regions via Notch1 signaling activation. <i>Experimental Neurology</i> , 2018, 304, 30-40.	4.1	32
10	Far Upstream Element-Binding Protein 1 Regulates LSD1 Alternative Splicing to Promote Terminal Differentiation of Neural Progenitors. <i>Stem Cell Reports</i> , 2018, 10, 1208-1221.	4.8	28
11	IMMU-38. TARGETING HYPOXIA DOWNSTREAM SIGNALING PROTEIN, CAIX FOR CAR-T CELL THERAPY AGAINST GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2018, 20, vi129-vi129.	1.2	0
12	The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 591-603.	2.9	38
13	Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1777-1788.	4.2	67
14	SDF-1/CXCR7 Chemokine Signaling is Induced in the Peri-Infarct Regions in Patients with Ischemic Stroke. , 2018, 9, 287.		22
15	A signature based on survival-related genes identifies high-risk glioblastomas harboring immunosuppressive and aggressive ECM characteristics. <i>Journal of Central South University (Medical)</i> Tj ETQq1 1 0x784314 r8BT /Over		
16	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. <i>Laboratory Investigation</i> , 2017, 97, 946-961.	3.7	24
17	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. <i>Neuro-Oncology</i> , 2017, 19, 1008-1010.	1.2	12
18	Adult IDH wild-type lower-grade gliomas should be further stratified. <i>Neuro-Oncology</i> , 2017, 19, 1327-1337.	1.2	177

#	ARTICLE	IF	CITATIONS
19	Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. <i>Nature Genetics</i> , 2017, 49, 75-86.	21.4	74
20	miR-491 regulates glioma cells proliferation by targeting TRIM28 in vitro. <i>BMC Neurology</i> , 2016, 16, 248.	1.8	28
21	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	7.2	448
22	Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation. <i>Medical Oncology</i> , 2016, 33, 99.	2.5	10
23	miR-124 suppresses the migration and invasion of glioma cells in vitro via Capn4. <i>Oncology Reports</i> , 2016, 35, 284-290.	2.6	43
24	Abscisic acid-induced cellular apoptosis and differentiation in glioma via the retinoid acid signaling pathway. <i>International Journal of Cancer</i> , 2016, 138, 1947-1958.	5.1	19
25	B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 2778-2790.	7.0	128
26	Extensive Therapies for Extraneural Metastases from Glioblastoma, as Confirmed with the OncoScan Assay. <i>World Neurosurgery</i> , 2016, 90, 698.e7-698.e11.	1.3	17
27	Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients. <i>Journal of Neuro-Oncology</i> , 2016, 127, 43-52.	2.9	15
28	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
29	Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases. <i>Journal of Neuro-Oncology</i> , 2016, 126, 499-507.	2.9	12
30	TRIM28 as an independent prognostic marker plays critical roles in glioma progression. <i>Journal of Neuro-Oncology</i> , 2016, 126, 19-26.	2.9	47
31	Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. <i>Oncotarget</i> , 2015, 6, 11882-11893.	1.8	68
32	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015, 6, 20885-20901.	1.8	42
33	MB-04 * EXPRESSION OF CRMP1 INHIBITS CELL PROLIFERATION OF MEDULLOBLASTOMA AND IS REGULATED BY HMGA1. <i>Neuro-Oncology</i> , 2015, 17, iii20-iii20.	1.2	0
34	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. <i>Trends in Molecular Medicine</i> , 2015, 21, 24-33.	6.7	628
35	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. <i>Modern Pathology</i> , 2015, 28, 177-186.	5.5	107
36	CRMP1 Inhibits Proliferation of Medulloblastoma and Is Regulated by HMGA1. <i>PLoS ONE</i> , 2015, 10, e0127910.	2.5	13

#	ARTICLE	IF	CITATIONS
37	TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. <i>Oncotarget</i> , 2015, 6, 24871-24883.	1.8	34
38	Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5327-35.	0.5	13
39	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11485-94.	0.5	11
40	Serological Identification of <i>URGCP</i> as a Potential Biomarker for Glioma. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 301-307.	3.9	12
41	Increased Expression of <i>Capn4</i> is Associated with the Malignancy of Human Glioma. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 521-527.	3.9	20
42	Structure and Cancer Immunotherapy of the B7 Family Member B7x. <i>Cell Reports</i> , 2014, 9, 1089-1098.	6.4	58
43	Glioma-Associated Antigen HEATR1 Induces Functional Cytotoxic T Lymphocytes in Patients with Glioma. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	2.2	22
44	Evidence of brain tumor stem progenitor-like cells with low proliferative capacity in human benign pituitary adenoma. <i>Cancer Letters</i> , 2014, 349, 61-66.	7.2	34
45	Astroblastoma: Rare Incidence and Challenges in the Pattern of Care. <i>World Neurosurgery</i> , 2014, 82, e125-e127.	1.3	8
46	To Err Is Human—Medicolegal Issues and Safe Care in Neurosurgery. <i>World Neurosurgery</i> , 2014, 81, 244-246.	1.3	7
47	B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. <i>Oncology Letters</i> , 2014, 8, 1195-1201.	1.8	51
48	Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e99490.	2.5	24
49	Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival. <i>Oncotarget</i> , 2014, 5, 6576-6583.	1.8	22
50	Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8627-36.	0.5	24
51	Treatment of Incidentally Discovered Low-Grade Gliomas: "Watch-and-Wait" or Not?. <i>World Neurosurgery</i> , 2013, 80, e121-e122.	1.3	9
52	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. <i>PLoS ONE</i> , 2013, 8, e67421.	2.5	25
53	B7-H4 expression is elevated in human U251 glioma stem-like cells and is inducible in monocytes cultured with U251 stem-like cell conditioned medium. <i>Chinese Journal of Cancer</i> , 2013, 32, 653-660.	4.9	12
54	Differential proliferative index of cancer stem-like cells in primary and recurrent medulloblastoma in human. <i>Child's Nervous System</i> , 2012, 28, 1869-1877.	1.1	10

#	ARTICLE	IF	CITATIONS
55	The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 149-157.	2.9	37
56	B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. <i>Neuro-Oncology</i> , 2009, 11, 757-766.	1.2	80
57	Brain tumor stem cells: view from cell proliferation. <i>World Neurosurgery</i> , 2009, 71, 274-279.	1.3	9
58	B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. <i>Journal of Neuro-Oncology</i> , 2008, 89, 121-129.	2.9	65